Find clinical trials

We have selected two potential anti-Epstein-Barr virus therapies (spironolactone and famciclovir) to test in an innovative multi-stage, multi-arm trial in order to identify the best treatment for progressive MS. Treatments will be compared to dummy-treatment.

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.

This proposed study 817P203, is a Phase 2 double-blind, randomised, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures. The study is planned to involve approximately 258 participants aged 18 to 70 years who have focal onset seizures at multiple study sites worldwide in the United States, Europe, and Asia Pacific. The study will have two groups of participants will be randomly assigned in a 2:1 ratio to SPN-817 (3.0 to 4.0 mg twice daily [BID]) or placebo, respectively, to achieve approximately 180 participants globally completing the study. The duration of treatment with SPN-817 or placebo will be approximately 22 to 24 weeks. The Primary Objective is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures. The Secondary Objectives are to evaluate the safety and tolerability of SPN-817 as a treatment for adult participants with focal onset seizures, and to characterize the pharmacokinetics (PK) of huperzine A after multiple dose administrations of SPN-817 (population PK analysis).